Hanyang UniversityOpportunity Contact
James Noh, CEO
Seoul, South Korea

Hanyang University Website
TherapeuticPreclinical Pharmalicensing.com

We identify a cell-permeable peptide, dNP2, which efficiently delivers proteins into mouse and human T cells, as well as various tissues.

We identify a cell-permeable peptide, dNP2, which efficiently delivers proteins into mouse and human T cells, as well as various tissues. Moreover, it enters the brain tissue and resident cells through blood vessels by penetrating the tightly organized blood–brain barrier. Then, we developed cytoplasmic domain of CTLA-4 (ctCTLA-4) peptide without its ligand interacting domain by conjugating BBB-penetrating peptide, dNP2 (dNP2-ctCTLA-4). We found that this dNP2-ctCTLA-4 could be able to induce Foxp3 expression in T cells which is important marker for regulatory T cells dependent on TGF-β. Moreover, dNP2-ctCTLA-4 treatment in vivo remarkably controls EAE progression by increase of Treg cells, which assures prolonged suppression of disease relapse.

Description of Technology

Technique 1: Novel blood-brain barrier-penetrating peptide, dNP2.

dNP2 is a novel 24-amino acids in length BBB-penetrating peptide of human origin.

Protein delivery efficiency of dNP2 in brain and spinal cord. (a) Mouse brains were observed at 40 min after injection via multi-photon confocal microscopy using a 3D lateral view and 3D top view or magnified 3D top view. (b) The fluorescent diffusion of the dNP2-dTomato protein out of blood vessels in the brain was monitored from 20–120 min. (c) Co-localization of the dNP2-dTomato (red) signal with fluorescent signals specific for various cell types, including neurons (NeuN, green), astrocytes(GFAP, green), and microglia (Iba-1, green). White boxes in the merged images are magnified regions. (d) The cellular localization of the dNP2-dTomato protein in the brain or spinal cord tissues in EAE mouse model. (e) The co-localization of the dNP2-dTomato protein with CD4-positive cells (green).

Technique 2: Regulatory T cell inducing drug candidate for multiple sclerosis therapy.

dNP2-ctCTLA-4 was constructed by conjugating BBB-penetrating peptide, dNP2, and cytoplasmic domain of CTLA-4 protein.

dNP2-ctCTLA-4 inhibited the T cell activation and proliferation in both mouse and human CD4 T cells upon anti-CD3/28 TCR stimulation.

Treatment of dNP2-ctCTLA-4 converts Th17 to Foxp3-expressing Tregs and dNP2-ctCTLA-4-induced Foxp3+ T cells showed similar characteristics with iTreg at transcript level.

Foxp3-expressing Tregs were increased and both IFNγ-expressing Th1 and IL-17-expressing Th17 cells were significantly reduced by administration of dNP2-ctCTLA-4 in the spinal cord of EAE-induced mouse.

Administration of dNP2-ctCTLA-4 effectively suppressed relapse in relapse-remitting EAE model.

Type of Business Relationship Sought
Out license, Partnership

The pace of change in our world continues to accelerate.  We all see this play out on the grand stage daily:  new diseases, warming oceans, increased hurricanes and fires, supply shortages, changes in social behaviors, more focus on alternative energies; the list goes on and on.  
We all have a role in proactively preparing for the ongoing shifts that we will encounter.  Our passionate team at Cognis Group is focused on helping you navigate innovation potential for the greatest collective benefits to people, the planet, and long term profits.

For more information, contact us:
US: +1 303 709 3157
UK: +44 1904 435190